Pathology: non squamous - mNSCLC - L1 - Wild Type (WT);
non squamous - mNSCLC - L1 - Wild Type (WT) | |||
KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | ||
pembrolizumab plus SoC | 1 | T1 | |
pembrolizumab and pemetrexed plus platin | 1 | T1 | |
placebo plus SoC | 0 | T0 | |
pemetrexed plus platin | 0 | T0 |